Thursday, November 9, 2023
8:16 AM EST – Oncolytics Biotech Inc. : Announced the presentation of positive, interim results from the Phase 1/2 GOBLET study evaluating the combination of pelareorep and atezolizumab in second-line patients with unresectable squamous cell carcinoma of the anal canal by Dirk Arnold, M.D., Ph.D., Director of Asklepios Tumorzentrum Hamburg, and primary investigator of the GOBLET trial, in an oral presentation at the 2nd International Multidisciplinary Anal Cancer Conference 2023, taking place in Rome, Italy. “The positive interim data from the anal cancer cohort of the Phase 2 GOBLET study presented today at the IMACC meeting is very exciting for our company and the potential of pelareorep in gastrointestinal cancers. These results met the pre-specified success criteria for the cohort and exceeded the results from historical controls in similar patient populations1-7,” said Dr. Matt Coffey, President and Chief Executive Officer of Oncolytics. Oncolytics Biotech Inc. (T.ONC) shares were -$0.02 at 2.15.
Stocks in Play: Oncolytics Biotech Inc. , Thu, 09 Nov 2023 08:27:06 EST